Drug intelligence / Profile preview

VI-0809

Development stage: Unknown
Lead developer: VIVUS LLC

Overview

VI-0809 is an investigational drug candidate currently in Phase 1 clinical development for the treatment of diabetes. Developed by VIVUS, a specialty pharmaceutical company focused on metabolic and orphan diseases, the compound is part of an early-stage pipeline that includes other metabolic candidates like VI-0810. As of current public disclosures, VIVUS has not released specific information regarding the molecular target, mechanism of action, or chemical modality of VI-0809, maintaining the program's details as proprietary.

Beyond the preview

Go deeper on VI-0809.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VI-0809.

Explore the full profile